Private and public payers, as well as patients, want access and have been calling for lower list prices
These trials have targeted various groups, including individuals with diabetes, focusing on cognitive effects, and those with or at risk of AD or PD (summarized in Table 2 for AD and Table 3 for PD)
However, he says, These symptoms could have come from a GI bug going around. But P.B
Back Flint, A, Raben, A, Astrup, A, Holst, JJ (1 Feb 1998) 'Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans', The Journal of Clinical Investigation , 101/3, 515-20
Higher doses have not been studied in published trials
Secondary end points included change from baseline in fasting plasma glucose (FPG), postprandial glucose ( PPG) and body weight